Adrenomyeloneuropathy (AMN)
Spur Therapeutics has made the difficult decision to discontinue clinical development of SBT101 for adrenomyeloneuropathy (AMN). This decision was not based on safety concerns, but rather on the increasingly complex development path for the program. Spur is working with the clinical community to share data from the SBT101 program, which includes the Phase 1/2 PROPEL study and the CYGNET natural history study. They hope that the insights gained from these studies will help support ongoing and future research efforts, ultimately contributing to the development of effective treatments for AMN.